In particular, the meta-analysis by Zhang et al. involved 2 of the cohort [24], [29] and 2 of the case-control [23], [28] studies included in ours and 1 case-control study [22] that we excluded because reported the estimates of BC risk and allele frequency only among cases carrying a germline mutation in BRCA1 and BRCA2 and not for controls. The gene discussed is BRCA1; the disease is breast cancer.